Pharmacogenomic test that predicts response to β2 -agonists in adults with asthma is cost effective

Personalized Medicine
Ann Chen WuAnne L Fuhlbrigge

Abstract

Pharmacogenomic tests that predict which asthma patients are likely to respond to β2-agonists hold promise to improve care for asthma. To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to β2-agonists might or might not be an appropriate, cost-effective option. We synthesized published data on clinical and economic outcomes in adults 18-35 to project 10-year costs, quality-adjusted life years and cost-effectiveness of pharmacogenomic testing for β2-agonist response. Pharmacogenomic testing for β2-agonist response conferred a cost-effectiveness ratio of $13,700 per quality-adjusted life year gained compared with no testing. Pharmacogenomic testing for β2-agonist response in individuals with asthma is potentially cost effective and should be pursued by test developers.

References

Nov 12, 1992·The New England Journal of Medicine·D S PearlmanS W Yancey
Dec 1, 1992·Postgraduate Medical Journal·P J Barnes, T H Lee
Mar 26, 1992·The New England Journal of Medicine·K B WeissT A Hodgson
Mar 1, 1993·American Journal of Respiratory Cell and Molecular Biology·E ReihsausS B Liggett
Jan 7, 1999·The European Respiratory Journal·J Serra-BatllesJ Brugués
Mar 8, 1996·The Journal of Ambulatory Care Management·J A CoventryP M Collins
Jul 3, 1999·American Journal of Respiratory and Critical Care Medicine·R StanfordL J Okamoto
Mar 7, 2001·Nature Medicine·S B Liggett
May 22, 2001·British Medical Bulletin·J M DrazenT H Lee
Jul 12, 2001·The Journal of Allergy and Clinical Immunology·A D PaltielK M Kuntz
Jun 6, 2003·The Journal of Allergy and Clinical Immunology·Miriam G CisternasEdward H Yelin
Mar 31, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Marilyn L MoyPeter J Neumann
Sep 16, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Hans-Georg EichlerBengt Jönsson
Nov 2, 2004·The European Respiratory Journal·N C ThomsonE Livingston
Feb 8, 2006·The Journal of Allergy and Clinical Immunology·Anne L FuhlbriggeA David Paltiel
Oct 2, 2007·The Journal of Allergy and Clinical Immunology·Ann C WuAnne L Fuhlbrigge
Feb 8, 2008·The New England Journal of Medicine·Simon MallalUNKNOWN PREDICT-1 Study Team
Jul 12, 2008·American Journal of Respiratory and Critical Care Medicine·Augusto A LitonjuaScott T Weiss
Sep 19, 2009·Pharmacogenomics·Blanca E HimesScott T Weiss
Dec 25, 2009·Pharmacogenetics and Genomics·Ann Chen WuScott T Weiss
Oct 7, 2010·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Rita K CydulkaAnthony Muni
Jan 29, 2011·Clinical Pharmacology and Therapeutics·M V Relling, T E Klein
Sep 10, 2011·Drug Discovery Today·Kalipso Chalkidou, Michael Rawlins
Mar 20, 2013·The Pharmacogenomics Journal·Q L DuanK G Tantisira
Aug 8, 2014·Expert Opinion on Drug Metabolism & Toxicology·John J Lima
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Jan 7, 2015·American Journal of Respiratory and Critical Care Medicine·Elliot IsraelUNKNOWN SHARP Investigators

❮ Previous
Next ❯

Software Mentioned

Risk

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.